CUVL 6-K
Clinuvel Pharmaceuticals Ltd (CUVL)
UNITEDSTATES
SECURITIESAND EXCHANGE COMMISSION
Washington,D.C. 20549
FORM6-K
REPORTOF FOREIGN PRIVATE ISSUER
PURSUANTTO RULE 13a-16 OR 15d-16
UNDERTHE SECURITIES EXCHANGE ACT OF 1934
Forthe month of July 2026
CommissionFile Number: 001-43353
CLINUVELPHARMACEUTICALS LIMITED
Level22, 535 Bourke Street
Melbourne,VIC 3000
Australia
(Addressof principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
INFORMATIONCONTAINED IN THIS FORM 6-K REPORT
On July 27, 2026, Clinuvel Pharmaceuticals Limited filed with the Australian Securities Exchange an announcement captioned “Appendix 3H - Notification of cessation of securities”, a copy of which announcement is attached to this Form 6-K as Exhibit 99.1.
Exhibits
| Exhibit No. | Description | |
|---|---|---|
| 99.1 | Announcement dated July 27, 2026 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| CLINUVEL PHARMACEUTICALS LIMITED | ||
|---|---|---|
| Date:<br> July 27, 2026 | By: | /s/ Philippe Wolgen |
| Name: | Philippe<br> Wolgen | |
| Title: | Managing<br> Director and Chief Executive Officer |
Exhibit 99.1
